(-)-Epigallocatechin gallate prevents carbon tetrachloride-induced rat hepatic fibrosis by inhibiting the expression of the PDGFRβ and IGF-1R

Chemico-Biological Interactions

Volumn 182, Issue 2-3, 2009, Pages 159-164

  Yasuda, Yoichi ^a   Shimizu, Masahito ^a   Sakai, Hiroyasu ^a   Iwasa, Junpei ^a   Kubota, Masaya ^a   Adachi, Seiji ^a   Osawa, Yosuke ^a   Tsurumi, Hisashi ^a   Hara, Yukihiko ^b   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Hara Office Inc   (Japan)

Author keywords

CCl4; EGCG; IGF 1R; Liver fibrosis; PDGFR

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; CARBON TETRACHLORIDE; EPIGALLOCATECHIN GALLATE; HYDROXYPROLINE; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SOMATOMEDIN C RECEPTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL ACTIVATION; CONTROLLED STUDY; DRUG TARGETING; LIVER CELL; LIVER FIBROSIS; MALE; NONHUMAN; PRIMARY PREVENTION; PROTEIN EXPRESSION; RAT; STELLATE CELL;

ACTINS; ALANINE TRANSAMINASE; ANIMALS; ANTICARCINOGENIC AGENTS; ASPARTATE AMINOTRANSFERASES; CARBON TETRACHLORIDE; CATECHIN; GENE EXPRESSION; LIVER; LIVER CIRRHOSIS; MALE; RATS; RATS, WISTAR; RECEPTOR, IGF TYPE 1; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RNA, MESSENGER;

RATTUS;

EID: 70350130982     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2009.07.015     Document Type: Article

References (25)

1. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 134 (2008) 1655-1669
2. Fattovich G., Stroffolini T., Zagni I., and Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127 (2004) S35-S50
3. Yoshida H., Tateishi R., Arakawa Y., Sata M., Fujiyama S., Nishiguchi S., Ishibashi H., Yamada G., Yokosuka O., Shiratori Y., and Omata M. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 53 (2004) 425-430
4. Shiratori Y., Imazeki F., Moriyama M., Yano M., Arakawa Y., Yokosuka O., Kuroki T., Nishiguchi S., Sata M., Yamada G., Fujiyama S., Yoshida H., and Omata M. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann. Intern. Med. 132 (2000) 517-524
5. Borkham-Kamphorst E., van Roeyen C.R., Ostendorf T., Floege J., Gressner A.M., and Weiskirchen R. Pro-fibrogenic potential of PDGF-D in liver fibrosis. J. Hepatol. 46 (2007) 1064-1074
6. Wong L., Yamasaki G., Johnson R.J., and Friedman S.L. Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J. Clin. Invest. 94 (1994) 1563-1569
7. Pinzani M., Milani S., Herbst H., DeFranco R., Grappone C., Gentilini A., Caligiuri A., Pellegrini G., Ngo D.V., Romanelli R.G., and Gentilini P. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. Am. J. Pathol. 148 (1996) 785-800
8. Yang C.S., Maliakal P., and Meng X. Inhibition of carcinogenesis by tea. Annu. Rev. Pharmacol. Toxicol. 42 (2002) 25-54
9. Shimizu M., Deguchi A., Lim J.T., Moriwaki H., Kopelovich L., and Weinstein I.B. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin. Cancer Res. 11 (2005) 2735-2746
10. Shimizu M., Shirakami Y., Sakai H., Adachi S., Hata K., Hirose Y., Tsurumi H., Tanaka T., and Moriwaki H. (-)-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male C57BL/KsJ-db/db mice. Cancer Prev. Res. 1 (2008) 298-304
11. Shimizu M., Shirakami Y., Sakai H., Tatebe H., Nakagawa T., Hara Y., Weinstein I.B., and Moriwaki H. EGCG inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells. Cancer Lett. 262 (2008) 10-18
12. Sachinidis A., Seul C., Seewald S., Ahn H., Ko Y., and Vetter H. Green tea compounds inhibit tyrosine phosphorylation of PDGF beta-receptor and transformation of A172 human glioblastoma. FEBS Lett. 471 (2000) 51-55
13. Novosyadlyy R., Dudas J., Pannem R., Ramadori G., and Scharf J.G. Crosstalk between PDGF and IGF-I receptors in rat liver myofibroblasts: implication for liver fibrogenesis. Lab. Invest. 86 (2006) 710-723
14. Yoshiji H., Noguchi R., Kuriyama S., Ikenaka Y., Yoshii J., Yanase K., Namisaki T., Kitade M., Masaki T., and Fukui H. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 288 (2005) G907-G913
15. Ogiso T., Nagaki M., Takai S., Tsukada Y., Mukai T., Kimura K., and Moriwaki H. Granulocyte colony-stimulating factor impairs liver regeneration in mice through the up-regulation of interleukin-1beta. J. Hepatol. 47 (2007) 816-825
16. Shimizu M., Hara A., Okuno M., Matsuno H., Okada K., Ueshima S., Matsuo O., Niwa M., Akita K., Yamada Y., Yoshimi N., Uematsu T., Kojima S., Friedman S.L., Moriwaki H., and Mori H. Mechanism of retarded liver regeneration in plasminogen activator-deficient mice: impaired activation of hepatocyte growth factor after Fas-mediated massive hepatic apoptosis. Hepatology 33 (2001) 569-576
17. Tomita H., Yamada Y., Oyama T., Hata K., Hirose Y., Hara A., Kunisada T., Sugiyama Y., Adachi Y., Linhart H., and Mori H. Development of gastric tumors in Apc(Min/+) mice by the activation of the beta-catenin/Tcf signaling pathway. Cancer Res. 67 (2007) 4079-4087
18. Kociok N., Radetzky S., Krohne T.U., Gavranic C., and Joussen A.M. Pathological but not physiological retinal neovascularization is altered in TNF-Rp55-receptor-deficient mice. Invest. Ophthalmol. Vis. Sci. 47 (2006) 5057-5065
19. Saito T., Akutsu S., Urushiyama T., Ishibashi K., Nakagawa Y., Shuler C.F., and Yamane A. Changes in the mRNA expressions of insulin-like growth factors, their receptors, and binding proteins during the postnatal development of rat masseter muscle. Zoolog. Sci. 20 (2003) 441-447
20. Chen A., and Zhang L. The antioxidant (-)-epigallocatechin-3-gallate inhibits rat hepatic stellate cell proliferation in vitro by blocking the tyrosine phosphorylation and reducing the gene expression of platelet-derived growth factor-beta receptor. J. Biol. Chem. 278 (2003) 23381-23389
21. Shimizu M., Deguchi A., Joe A.K., McKoy J.F., Moriwaki H., and Weinstein I.B. EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells. J. Exp. Ther. Oncol. 5 (2005) 69-78
22. Rubini M., Werner H., Gandini E., Roberts Jr. C.T., LeRoith D., and Baserga R. Platelet-derived growth factor increases the activity of the promoter of the insulin-like growth factor-1 (IGF-1) receptor gene. Exp. Cell Res. 211 (1994) 374-379
23. Bridle K.R., Li L., O'Neill R., Britton R.S., and Bacon B.R. Coordinate activation of intracellular signaling pathways by insulin-like growth factor-1 and platelet-derived growth factor in rat hepatic stellate cells. J. Lab. Clin. Med. 147 (2006) 234-241
24. Zhen M.C., Wang Q., Huang X.H., Cao L.Q., Chen X.L., Sun K., Liu Y.J., Li W., and Zhang L.J. Green tea polyphenol epigallocatechin-3-gallate inhibits oxidative damage and preventive effects on carbon tetrachloride-induced hepatic fibrosis. J. Nutr. Biochem. 18 (2007) 795-805
25. Nakamoto K., Takayama F., Mankura M., Hidaka Y., Egashira T., Ogino T., Kawasaki H., and Mori A. Beneficial effects of fermented green tea extract in a rat model of non-alcoholic steatohepatitis. J. Clin. Biochem. Nutr. 44 (2009) 239-246